Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Patent Reform Legislation Introduced; Damages, Inequitable Conduct In Flux

  • News

Executive Summary

Senate language from the patent reform debate in the last Congress will be the starting point this year for negotiations on how to calculate a reasonable royalty for patent infringement

You may also be interested in...



Patent Reform: Brands Get Damages, Generics Have Inequitable Conduct

Patent reform legislation exited the Senate Judiciary Committee April 2 without apportionment of damages or inequitable conduct language, providing both brand and generic pharmaceutical companies with something to like

Patent Reform: Brands Get Damages, Generics Have Inequitable Conduct

Patent reform legislation exited the Senate Judiciary Committee April 2 without apportionment of damages or inequitable conduct language, providing both brand and generic pharmaceutical companies with something to like

Full House Judiciary Panel Getting Into The Patent Act: IP Issues Will No Longer Go Through Subcmte.

Change in jurisdiction eliminates one round of legislative review, gives Chairman Conyers direct control of issue.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By